EWTX Edgewise Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1710072 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY742.1%
TTM EPS YoY633.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE92.1%
ROA85.4%
ROIC (approx.)-16.6%
Asset turnover—
Leverage & solvency
Liabilities / assets8.3%
Debt / equity0.00x
Current ratio12.30x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.20x
Accruals ratio102.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $151.39M | $126.97M | $90.91M | $54.03M | $32.19M |
| SG&A expense | $40.02M | $31.87M | $23.45M | $17.63M | $11.03M |
| Operating income | -$191.41M | -$158.83M | -$114.36M | -$71.66M | -$43.22M |
| Pretax income | -$167.80M | -$133.80M | -$100.20M | — | — |
| Income tax | $4,000 | $3,000 | $4,000 | $0 | $0 |
| Net income | -$167.79M | -$133.81M | -$100.16M | -$67.64M | -$42.81M |
| EBITDA | -$189.32M | -$156.76M | -$112.81M | -$71.29M | -$42.94M |
| EPS (basic) | -1.63 | -1.45 | -1.57 | -1.26 | -1.14 |
| EPS (diluted) | -1.63 | -1.45 | -1.57 | -1.26 | -1.14 |
| Weighted avg. shares (diluted) | 102.93M | 92.41M | 63.72M | 53.59M | 37.53M |
| Balance sheet | |||||
| Cash & equivalents | $61.15M | $41.67M | $86.10M | $21.99M | $15.57M |
| Current assets | $543.38M | $475.48M | $327.00M | $357.00M | $283.77M |
| PP&E, net | $7.83M | $9.50M | $10.44M | $8.53M | $912,000 |
| Total assets | $552.60M | $486.82M | $340.04M | $367.10M | $285.23M |
| Current liabilities | $27.37M | $23.86M | $16.77M | $16.59M | $10.52M |
| Total liabilities | $30.35M | $27.60M | $21.20M | $20.39M | $10.85M |
| Shareholders' equity | $522.26M | $459.22M | $318.83M | $346.72M | $274.38M |
| Shares outstanding | 106.25M | 94.84M | 70.45M | 63.26M | 49.50M |
| Cash flow statement | |||||
| Operating cash flow | -$143.82M | -$109.03M | -$91.95M | -$52.63M | -$33.51M |
| Capital expenditure | $256,000 | $1.31M | $5.75M | $5.55M | $668,000 |
| Free cash flow | -$144.07M | -$110.34M | -$97.69M | -$58.18M | -$34.17M |
| Investing cash flow | -$32.79M | -$184.66M | $102.89M | -$70.58M | -$242.23M |
| Financing cash flow | $196.09M | $249.25M | $53.17M | $129.64M | $186.38M |
| Depreciation & amortization | $2.08M | $2.07M | $1.55M | $368,000 | $272,000 |
| Stock-based compensation | $34.75M | $24.71M | $17.56M | $10.92M | $4.40M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.